和元生物收盘上涨3.70%，最新市净率2.35，总市值38.16亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of He Yuan Biological Technology Co., Ltd., which focuses on gene therapy and related services [1][2] - As of the first quarter of 2025, the company reported a revenue of 52.85 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, representing a year-on-year decline of 41.04% [1] - The company's gross profit margin was reported at -36.44%, indicating challenges in profitability [1] Group 2 - He Yuan Biological has a current market capitalization of 3.816 billion yuan and a price-to-book ratio of 2.35 [1][2] - The company is among seven institutions holding shares, with a total of 83.47 million shares valued at approximately 459 million yuan [1] - The industry average price-to-earnings ratio (PE) is 38.66, while He Yuan Biological's trailing PE is -11.25, indicating a significant underperformance compared to industry peers [2]